美第奇新星生物技术 MNOV 深 沪
已收盘 12-19 16:00:00 美东时间
1.43
-0.020
-1.38%
华盛通- 最 高1.45
- 今 开1.44
- 成交量 10.31万股
- 最 低 1.405
- 昨 收 1.45
- 总市值 7013.61万
- 52周最高 2.197
- 市盈率 静 --
- 换手率 0.21%
- 52周最低 1.13
- 委 比 -77.55%
- 总股本 4904.62万
- 历史最高 14.50
- 量 比 1.96
- 振 幅 3.10%
- 历史最低 1.12
- 每 手 1
- 风险率 0.25%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多MediciNova Completes Patient Enrollment in Mid-Stage Trial for Chemotherapy Nerve Damage
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the successful completion of patient
12-18 19:08
美股大行评级 | 潜在涨幅2566.67%！Ascendiant Capital上调GRI Bio目标价至36美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从35美元升至36美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.75美元升至8美元
12-09 10:32
D. Boral Capital Maintains Buy on MediciNova, Maintains $9 Price Target
D. Boral Capital analyst Jason Kolbert maintains MediciNova (NASDAQ:MNOV) with a Buy and maintains $9 price target.
12-09 00:16
MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND
MediciNova, Inc. announced updates and basic characteristics data from its Phase 2b/3 clinical trial of MN-166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS), known as the COMBAT-ALS study. Presented at the 36th International Symposium on ALS/MND, the findings highlighted the trial's overview, study update, and baseline characteristics, including 234 randomized participants, with enrollment completed in September 2025. The data aligns with pr...
12-08 11:00
Message from the CEO to MediciNova Shareholders
MediciNova's MN-001 program has achieved a significant milestone with the publication of a study in the *Journal of Atherosclerosis and Thrombosis*. The research, conducted with a leading Japanese academic team, revealed that MN-002, the active metabolite of MN-001, enhances cholesterol efflux in macrophages via ABCA1 and ABCG1 upregulation, a key step in Reverse Cholesterol Transport (RCT). This mechanism underscores MN-001's potential to addres...
12-01 23:00
MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor
MediciNova appoints Dr. Christopher D. Breder, a seasoned physician-scientist and regulatory expert with over two decades of experience at the FDA and major pharmaceutical companies, as Clinical and Regulatory Advisor. Dr. Breder will guide MediciNova’s drug development programs and lead its Scientific Advisory Board. His expertise in clinical trial design, regulatory strategy, and novel therapies in neuroscience and rare diseases will support Me...
11-18 11:00
MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards
MediciNova, Inc. has won the "Contract Research and Development Innovation Award" at the Fifth Annual BioTech Breakthrough Awards for advancing MN-166 (ibudilast), a novel small molecule drug candidate targeting neuroinflammation and neuroprotection in diseases like amyotrophic lateral sclerosis (ALS). The company highlighted its commitment to treating unmet medical needs through ongoing Phase 2/3 trials for ALS and other conditions.
11-06 23:00
MediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
MediciNova, Inc. announced the completion of patient enrollment in its Phase 2 clinical trial (MN-001-NATG-202) evaluating MN-001 (Tipelukast) for treating hypertriglyceridemia and non-alcoholic fatty liver disease (NAFLD) in Type 2 diabetes (T2DM) patients. The trial is a multi-center, randomized, double-blind, placebo-controlled study where patients receive either 500 mg/day of MN-001 or placebo for 24 weeks. Primary endpoints are changes in li...
11-04 12:00
美股大行评级 | 苹果、亚马逊、Cloudflare、西部数据、Twilio等获十多家机构集体上调目标价；杰富瑞首予Cloudflare"持有"评级，目标价250美元
今日重点评级关注：康托·菲茨杰拉德：维持Cabaletta Bio"超配"评级，目标价从15美元升至30美元；HC Wainwright & Co.：维持Invivyd"买入"评级，目标价从5美元升至10美元
11-03 20:20
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Alphatec Holdings (NASDAQ:ATEC) shares rose 21.7% to $19.88 during Fri...
10-31 20:10
